Navigation Links
AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
Date:3/1/2012

IRVINE, Calif., March 1, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has initiated the first shipment of AHRO-001 Active Pharmaceutical Ingredient (API) to its research and development partner CardioNova, Ltd., a Russia based biotech company responsible for Phase 1 and 2 human clinical studies of AHRO-001. The clinical-grade material will be used to commence the toxicology studies conducted for Russian regulatory purposes.

"We are pleased to announce this first shipment, clearly a milestone for us in the development of AHRO-001 for use in upcoming human clinical studies," said AtheroNova CEO Thomas Gardner. "This is the highest purity ever achieved in AHRO-001 and is ready to be used in an advanced clinical setting for the first time. As we proceed through our clinical phases, we are extremely gratified to adhere to our aggressive development path and look forward to additional development milestones in the coming months."

"CardioNova is very excited to receive the first shipment," commented CardioNova CEO Andrey Boldyrev. "We are looking forward to starting the toxicology studies and initiating clinical studies in close cooperation with AtheroNova, who proves to be an ideal partner for this project. We believe that an effective partnership of our two companies will allow us to bring to market a novel drug that is much anticipated by doctors and patients all over the world."

About AHRO-001
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are the
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Announces a New Board Member
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
5. GenVec Achieves Second Milestone in Collaboration
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
9. New compact microspectrometer design achieves high resolution and wide bandwidth
10. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
11. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... -- Traffic.com, Inc., has launched interactive, personalized services ... www.traffic.com , the company announced Thursday. Traffic.com will ... immediate, at-a-glance displays of roadway traffic conditions including ... it said in a news release. , ,Data ...
... Telecommunications, Inc., has expanded its business continuance practice ... , ,The new service provides customers with ... basis for critical data. The disk-based system delivers ... unlike tape back-up systems, the company said. , ...
... - The Tascon Group has launched the Tascon Business Analyst ... job costing. , ,The Business Analyst is being offered as ... . , ,The program is based on a business valuation ... - a system known as the optimization method. , ,"It ...
Cached Biology Technology:
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 15, 2014 The ... make it easier to detect and prevent counterfeit ... Today the agency started performing an in-house ... will validate the authenticity of purchased microcircuits while ... new quality control measures will be conducted at ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tummy,s taste for red wine with red meat , ... when red wine meets red meat? If the rendezvous happens ... of healthful chemical compounds may thwart formation of harmful substances ... which reinforces the benefits of consuming wine and other foods ...
... at Chicago have identified a novel function for an enzyme ... respiratory distress syndrome, also known as ARDS. The finding ... of lung inflammation and injury. The research will be published ... and online June 29. ARDS is an often fatal ...
... times larger than their wild relatives. How did they ... larger fruits, heads of grain, tubers, etc, because this is ... for food. In addition to size, tomatoes have been ... it has been difficult to study these traits in tomatoes, ...
Cached Biology News:American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9UIC researchers make promising finding in severe lung disease 2Evolution of fruit size in tomato 2Evolution of fruit size in tomato 3
... Activity Kit ADAM17 Activity Kit TNF-α Converting ... PROTECT FROM LIGHT. AVOID FREEZE/THAW CYCLES. The ... and sensitive assay designed to measure human ... samples and for screening enzyme inhibitors. An ...
... unique agarose-digesting enzyme developed by Promega for ... or RNA from agarose gels. The enzyme ... (LMP) agarose melted at 6575C does not ... temperature before hydrolysis. Simply place the tube ...
...
... FREEZE. Nuclear matrix proteins (NMPs) make up the ... associated with such functions as DNA replication, RNA ... matrix has been shown to be highly insoluble ... that cell death releases soluble nuclear matrix proteins ...
Biology Products: